Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

12 evidence topics · 14 sources

Summary: limitations of complement inhibitor therapy

Two intravitreal complement inhibitors are approved by the FDA for geographic atrophy: pegcetacoplan (C3 inhibitor), given every 25 to 60 days, and avacincaptad pegol (C5 inhibitor), given once monthly (approximately every 28 ± 7 days). Both reduced the growth of geographic atrophy lesions in sham-controlled phase 3 trials (pegcetacoplan by 22% monthly and 18% every other month at 24 months in OAKS; avacincaptad pegol by 14% in square-root-transformed growth at 12 months and by 14% at 24 months with monthly dosing in GATHER2). Neither improved visual function: the AAO Preferred Practice Pattern states that “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol”, and the 2023 Cochrane review of 10 randomized trials (4052 participants) found “no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD”. The avacincaptad pegol finding of fewer eyes with persistent vision loss comes from a post hoc analysis of 12-month data.

Treatment requires indefinite intravitreal injections. In OAKS and DERBY, 21% to 31% of participants in the pegcetacoplan arms discontinued treatment before month 24. In a retrospective real-world cohort of eyes treated with pegcetacoplan or avacincaptad pegol, retention declined over the first 12 months, and pegcetacoplan treatment (hazard ratio 3.32), new neovascular AMD (odds ratio 3.02), and poor baseline visual acuity were associated with attrition.

Both products increase conversion to neovascular AMD: 12% with monthly and 7% with every-other-month pegcetacoplan against 3% with control by month 24, and 12% with avacincaptad pegol against 9% with sham over 24 months in GATHER2. Pegcetacoplan carries a warning for retinal vasculitis and/or retinal vascular occlusion, which may occur with the first dose and may cause severe vision loss. A postmarketing case series confirmed retinal vasculitis in 14 eyes of 13 patients, all after the first injection, with a more than 6-line loss of visual acuity in 6 eyes (43%); the guideline cites a postmarketing rate of 0.01% per injection. No retinal vasculitis was reported in the pivotal trials, which had no protocol for angiography in eyes with intraocular inflammation.

Neither product is authorized in the European Union. The European Medicines Agency confirmed its recommendation to refuse marketing authorisation for pegcetacoplan on 19 September 2024 because slowing lesion growth “did not lead to clinically meaningful benefits for patients”, and Astellas withdrew its application for avacincaptad pegol on 24 October 2024 after the Agency's provisional opinion that the product could not have been authorised. NICE suspended its appraisal of pegcetacoplan in February 2025, after the company reported that it did not receive marketing authorisation from the MHRA and has since discontinued it. The guideline notes that long-term, real-world data for both products are lacking.

Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events

“Ten RCTs with 4052 participants and eyes with GA were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For 242 participants in one study, pegcetacoplan probably did not meaningfully change BCVA given monthly (+1.05 letters, 95% CI −2.71 to 4.81) or EOM (−1.42 letters, 95% CI −5.25 to 2.41), as supported by moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These reductions correspond to 19.2% and 14.8% versus sham, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a study of 260 participants with extrafoveal or juxtafoveal GA, monthly avacincaptad pegol probably did not result in a clinically meaningful change in BCVA at 2 mg (+1.39 letters, 95% CI −5.89 to 8.67) or 4 mg (−0.28 letters, 95% CI −8.74 to 8.18), based on moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, there is currently no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD; further results from the phase 3 studies of pegcetacoplan and avacincaptad pegol are eagerly awaited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Intravitreal administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other intravitreal therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote